Anti-thrombotic agents derived from snake venom proteins. Issue 1 (October 2016)

• Record Type: Journal Article
• Authors: Huang, Tur-Fu; Hsu, Chun-Chieh; Kuo, Yu-Ju
• Is Part Of: Thrombosis journal. Volume 14:Issue 1(2016)
• Page Start: 145
• Page End: 149
• Publication Date: 2016-10
• Subjects: Snake venom proteins -- Disintegrins -- Antithrombotic agent -- Arterial thrombosis -- Angiogenesis -- Septic inflammation; Thrombosis -- Periodicals; 616.135005
• DOI: 10.1186/s12959-016-0113-1
• Languages: English
• ISSNs: 1477-9560

Abstract

Abstract Snake venoms affect blood coagulation and platelet function in a complex manner. However, two classes of venom proteins, snaclecs and disintegrins have been shown to specifically target receptors including GPIb, α2β1, GPVI, CLEC-2 and integrins αIIbβ3, αvβ3, α5β1 expressed on platelets, endothelial cells, phagocytes, tumor cells, thus affecting cell-matrices and cell-cell interactions. Here, we focus on disintegrins, a class of low molecular mass Arg-Gly-Asp(RGD)/Lys-Gly-Asp(KGD)-containing, cysteine-rich polypeptide derived from various viper snake venoms. This review describes the potential applications of disintegrins in field of integrin-related diseases, especially arterial thrombosis, angiogenesis, tumor progression and septic inflammation. In addition, a novel RGD-containing disintegrin TMV-7 is being developed as a safer antithrombotic agent with minimal side effects, such as thrombocytopenia and bleeding.